Citigroup Upgrades Bio-Rad Laboratories to Buy, Raises Price Target to $400
Portfolio Pulse from Benzinga Newsdesk
Citigroup has upgraded Bio-Rad Laboratories from Neutral to Buy, increasing the price target from $350 to $400.
October 01, 2024 | 1:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup analyst Patrick Donnelly has upgraded Bio-Rad Laboratories from Neutral to Buy, raising the price target from $350 to $400.
The upgrade from Neutral to Buy by Citigroup, along with a raised price target, is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100